Cart (0 Items)
Your cart is currently empty.
View ProductsStable Isotope Labelled Tovetumab Biosimilar – Anti-PDGFRA / PDGFR2/ CD140a mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Isotope Labelled Tovetumab Biosimilar - Anti-PDGFRA / PDGFR2/ CD140a mAb - Research Grade |
|---|---|
| Source | CAS 1243266-04-7 |
| Species | Homo sapiens |
| Expression system | Mammalian cells |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | MS |
| Aliases /Synonyms | MEDI-575 |
| Reference | PX-TA1328-SIL |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG2-kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
Description of Stable Isotope Labelled Tovetumab Biosimilar - Anti-PDGFRA / PDGFR2/ CD140a mAb - Research Grade
General information on Anti-PDGFRA / PDGFR2/ CD140a[Homo sapiens] (Tovetumab) Monoclonal Antibody
Tovetumab has been investigated for the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
Reviews
Il n’y a pas encore d’avis.